Bristol Myers Squibb Company $BMY Shares Bought by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 88.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 134,307 shares of the biopharmaceutical company’s stock after acquiring an additional 62,870 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Bristol Myers Squibb were worth $7,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares in the last quarter. State Street Corp raised its stake in shares of Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after buying an additional 1,855,238 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. Finally, Bank of New York Mellon Corp increased its stake in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Bank of America dropped their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Price Performance

BMY stock opened at $55.64 on Tuesday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock’s fifty day simple moving average is $58.02 and its 200-day simple moving average is $56.65. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market capitalization of $113.61 billion, a price-to-earnings ratio of 15.63, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the firm earned $1.80 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.